EGFR and non-small cell lung carcinoma: The National Comprehensive Cancer Network (NCCN) 2021 guidelines now recommend adjuvant osimertinib for patients with completely resected EGFR mutation‐positive stage IIB‐IIIA NSCLC or high‐risk stage IB‐IIA NSCLC who received previous adjuvant chemotherapy or are ineligible to receive platinum‐based chemotherapy.12